Using advanced CT scans to monitor treatment in kidney cancer patients
Official title: Dual-energy SPEctral CT to Evaluate Response to New First-line Therapies in Patients With Metastatic Clear Cell REnal Cancer and the Association of Its Parameters With Molecular Alterations
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06863857 · Data updated 2026-11-12
This study tests if advanced CT scans can help track how well treatments are working for people with metastatic kidney cancer who are receiving new combination therapies.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Bologna, BO and 1 other locations) |
| Status | Recruiting |
| Started | September 30, 2024 |
| Main results expected | June 18, 2027 |
| Study ends | August 31, 2027 |
| Registry record updated | March 7, 2025 |
| Trial ID | NCT06863857 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a confirmed diagnosis of metastatic clear cell renal cancer who have not received prior treatment.
✕Probably not a fit
Patients with non-clear cell renal cancer or those who have previously undergone treatment for their condition may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of dual-energy spectral computed tomography (CT) in monitoring treatment responses in patients with metastatic clear cell renal cancer. It focuses on patients receiving first-line therapies that combine immunotherapy and targeted drugs. By analyzing changes in CT-derived parameters over time, the study aims to correlate these changes with treatment outcomes and molecular alterations in tumor tissue. The goal is to improve the understanding of how tumor characteristics evolve during therapy and their relationship with patient responses.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment strategies for patients with metastatic clear cell renal cancer.
How similar studies have gone: While the use of dual-energy spectral CT is a relatively novel approach in this context, similar imaging techniques have shown promise in other cancer types, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria * Age ≥ 18 years * Patients with histological or cytological diagnosis of clear cell RCC * Patients with metastatic disease documented by imaging or biopsy of the secondary site * Patients who have not had previous treatment for RCC * Patients with an indication for first-line medical treatment based on IO+TKI, IO+IO as per clinical practice at the Medical Oncology Unit of the IRCCS University Hospital of Bologna * Patients who have already had a dual-energy spectral total-body CT with MDC within 4 weeks of treatment initiation * Availability of a formalin-fixed, paraffin-embedded histological block (FFPE) stored for a period \<15 years, for the execution of molecular analysis for the search for alterations of the genes ATM, BAP1, KDM5C, MET, MTOR, NF2, PBRM1, PIK3CA, PTEN, SETD2, SMARCB1, TP53, TSC1, TSC2, VHL * Patients who knowingly express consent to participate in the study after signing the consent Exclusion Criteria -None
Where it's running
-
Irccs Azienda Ospedaliero Universitario Di Bologna
Bologna, Bo, Italy Recruiting -
Oncology Unit, IRCCS Azienda Ospedaliero Universitaria Bologna
Bologna, Italy Recruiting
Study contacts
- Principal investigator: Francesco Massari, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Francesco FM Massari, MD
- Email: francesco.massari@aosp.bo.it
- Phone: 0511242204
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Irreversible Electroporation for Recurrent Pelvic Tumors
This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
-
Hospital admissions for blood in the urine
This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Spectral CT during embolization and ablation for liver and kidney tumors
This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.
-
Image-guided stereotactic body radiotherapy for primary kidney cancer (STONE)
This will try high-dose, focused radiation (SBRT) to treat adults with a single small primary kidney cancer who are not good candidates for surgery or who decline surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.